Achilles K. Anagnostopoulos

Thessaloniki, ESYE12, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 186 publications

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy.

EASIX and m-EASIX predict severe cytokine release syndrome and overall survival after CAR T-cell therapy.

Journal: Blood vessels, thrombosis & hemostasis

Published: March 13, 2024

Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.

Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.

Journal: International journal of molecular sciences

Published: September 06, 2023

Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation.

Open-Label Randomized Controlled Study of Ciprofloxacin vs Rifaximin as Neutropenia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Transplantation proceedings

Published: August 21, 2023

Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.

Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.

Journal: Cancers

Published: July 04, 2023

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis.

Journal: Cancers

Published: May 18, 2023

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.

Journal: European journal of haematology

Published: February 13, 2023

Laparoscopic surgery in a child with a failing Fontan circulation.

Laparoscopic surgery in a child with a failing Fontan circulation.

Journal: Anaesthesia reports

Published: February 07, 2023

The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.

The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms.

Journal: American journal of hematology

Published: January 16, 2023

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Journal: Cancer

Published: December 11, 2022

T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations.

T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations.

Journal: Frontiers in oncology

Published: November 14, 2022

Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party.

Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party.

Journal: Bone marrow transplantation

Published: November 05, 2022

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.

SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.

Journal: Nature medicine

Published: November 04, 2022

Showing 1-12 of 186

Last Updated: 09/26/2026